Pretomanid Tablets and Rifampin Intravenous
Determining the interaction of Pretomanid Tablets and Rifampin Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration of pretomanid with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and antimicrobial effects of pretomanid, which has been shown to be a substrate of the isoenzyme. Following 7 days of concomitant administration, rifampin (600 mg daily) decreased systemic exposure (AUC) and peak plasma concentration (Cmax) of pretomanid by 66% and 53%, respectively. In another 7-day study, efavirenz (600 mg daily) decreased mean AUC and Cmax of pretomanid (200 mg daily) by 35% and 28%, respectively. MANAGEMENT: The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided. Dosage adjustments as well as clinical and laboratory monitoring of pretomanid should be considered whenever a strong or moderate CYP450 3A4 inducer is added to or withdrawn from therapy. References "Product Information. Pretomanid (pretomanid)." The Global Alliance for TB Drug Development, New York, NY.
Professional:GENERALLY AVOID: Coadministration of pretomanid with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and antimicrobial effects of pretomanid, which has been shown to be a substrate of the isoenzyme. Following 7 days of concomitant administration, rifampin (600 mg daily) decreased systemic exposure (AUC) and peak plasma concentration (Cmax) of pretomanid by 66% and 53%, respectively. In another 7-day study, efavirenz (600 mg daily) decreased mean AUC and Cmax of pretomanid (200 mg daily) by 35% and 28%, respectively.
MANAGEMENT: The use of pretomanid with strong or moderate CYP450 3A4 inducers should be avoided. Dosage adjustments as well as clinical and laboratory monitoring of pretomanid should be considered whenever a strong or moderate CYP450 3A4 inducer is added to or withdrawn from therapy.
- "Product Information. Pretomanid (pretomanid)." The Global Alliance for TB Drug Development, New York, NY.
Generic Name: pretomanid
Brand name:
Synonyms: Pretomanid
Generic Name: rifampin
Brand name: Rifadin, Rifadin IV, Rimactane
Synonyms: Rifampin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Pretomanid Tablets-Rifampin Oral, Intravenous
- Pretomanid Tablets-Rifampin, Isoniazid, and Pyrazinamide
- Pretomanid Tablets-Rifamycin
- Pretomanid Tablets-Rifamycin Sodium
- Pretomanid Tablets-Rifapentine
- Pretomanid Tablets-Rifater
- Rifampin Intravenous-Pretz-D
- Rifampin Intravenous-Prevacid
- Rifampin Intravenous-Prevacid 24 HR
- Rifampin Intravenous-Prevacid Injection
- Rifampin Intravenous-Prevacid Naprapac
- Rifampin Intravenous-Prevacid OTC